All In Biotech

Drug Trial Radar · NCT07810972

Evaluate the Safety and Efficacy of TJO-087

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TJO-087

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Actual

Start

Apr 6, 2026

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the therapeutic efficacy and safety of investigational product compared with placebo in adult patients with dry eye disease. Patients will receive investigational product or placebo for 3 months, and the therapeutic effect will be assessed based on the change in corneal staining score from baseline.

Conditions

  • Dry Eye Syndrome (DES)

Interventions

  • TJO-087Drug

    one drop in each eye, twice daily (1 drop of IP, 1 drop of placebo)

  • TJO-087Drug

    one drop in each eye, twice daily (2 dose of IP)

  • Vehicle (Placebo solution)Drug

    one drop in each eye, twice daily (2 dose of placebo)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Corneal Staining Score at 12 weeksTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.